Schering Aktiengesellschaft

Friedmund Neumann

Rudolf Wiechert

Henry Laurent

Helmut Hofmeister

Yukishige Nishino

Ursula Lachnit-Fixson

Klaus Prezewowsky

Albert Radlmaier

Hans-Udo Schweikert

Ursula Habenicht

Ursula-Friederike Habenicht

J&ouml;rg Elliesen

Ulf Tunn

Theodor Senge

The present invention concerns the combination of dehydroepiandrosterone (DHEA) and at least one aromatase inhibitor and the use of such a combination to produce a medicament for treating relative and/or absolute androgen deficiency in men. Selective aromatase inhibitors such as atamestan, formestan, pentrozol, aramidex, fadrozol, CGS 20267 and/or vorozol, are preferred for producing the medicament according to the invention.

Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men

Methods of treating androgen deficiency in men using selective aromatase

Aromatase-inhibitors are used in a method of prophylaxis and/or treatment by therapy of prostatic hyperplasia. Pharmaceutical preparations suitable for such a use comprise an aromatase-inhibitor. A particularly preferred aromatase-inhibitor is, for example, testolactone.

Use of aromatase-inhibitors for prophylaxis and/or treatment of benign

A pharmaceutical composition comprising an anti-estrogen and an antigonadotropically effective anti-androgen, e.g., in a weight ratio of anti-estrogen to anti-androgen of essentially 2:1 to 1:10 is effective for the prophylaxis and therapy of prostate hyperplasia. Suitable anti-estrogens include, for example, tamoxifen. Antigonadotropically active anti-androgens preferably are steroids having anti-androgenic and progestational properties, e.g., cyproterone acetate.

Combined antiestrogens and antigonadotropically effective antiandrogens

Relief from climacteric disturbances is achieved by administration of first a combination of an estrogen of type 1 and an estrogen of type 2, approximately in a ratio of 2:1 to 1:8, daily over 10-12 days; then a combination of an estrogen of type 1 and an estrogen of type 2, approximately in a ratio of 2:1 to 1:8, and a progestogen, daily over 9-11 days; and thereafter an estrogen of type 2, or a placebo, daily over 6-8 days.

Novel agents and novel methods for treatment of climacteric disturbances

Reliable relief of physical and psychological menopausal disturbances is achieved by administering a combination of estradiol estrogen or derivatives of estradiol (type 1) and estriol or a derivative of estriol (type 2) in a ratio of approximately 1 : 1 to 1 : 10 for 21 days and thereafter an estrogen of type 2, a placebo or no hormone for 7 days. Administration of the dosage for 28 days permits adaptation to the normal cycle of the female.

Novel agents and methods for treatment of climacteric disturbances

8.alpha.-Estratrienes of the formula ##SPC1## Wherein R is lower alkyl and X is an oxygen atom, a .beta.-hydroxy or .beta.-hydroxy-.alpha.-substituted or unsubstituted saturated or unsaturated hydrocarbon group, and the esters and ethers thereof, possess strong vaginotropic but only weak utertropic activity and are useful in the treatment of estrogenic deficiency conditions where uteral effects are not desired.

1,3-Oxygenated 8.alpha.-estratrienes

1,3-Dihydroxy-8.alpha.-estratrienes of the formula ##SPC1## Wherein R is lower-alkyl and --A--B is ##SPC2## Wherein R' is a saturated or unsaturated hydrocarbon group and R' is lower-alkyl, aralkyl or phenyl, and the esters and ethers thereof, possess strong vaginotropic but only weak utertropic activity and are useful in the treatment of estrogenic deficiency conditions where uteral effects are not desired.

Growing community of inventors

Berlin, Germany

Friedmund Neumann